Atypical hemolytic uremic syndrome: The role of complement pathway gene mutation analysis

Clinical Advances in Hematology and Oncology

Volumn 12, Issue 4, 2014, Pages 266-268

  Weitz, Ilene C ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT FACTOR H; COMPLEMENT FACTOR I; DIACYLGLYCEROL KINASE; ECULIZUMAB; MEMBRANE COFACTOR PROTEIN; NEPHRITIC FACTOR; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBOMODULIN; COMPLEMENT;

BLOOD TRANSFUSION; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; COST EFFECTIVENESS ANALYSIS; CYTOLYSIS; GENE MUTATION; GENE SEQUENCE; HEMOLYTIC UREMIC SYNDROME; HUMAN; NOTE; OPSONIZATION; GENETICS; MUTATION; NUCLEOTIDE SEQUENCE;

ATYPICAL HEMOLYTIC UREMIC SYNDROME; COMPLEMENT SYSTEM PROTEINS; DNA MUTATIONAL ANALYSIS; HUMANS; MUTATION;

EID: 84900010039     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (9)

1. Chaudhary P, Hepgur M, Sarkissian S, Smith RJ, Weitz IC. Atypical haemolytic-uraemic syndrome due to heterozygous mutations of CFH/CFHR1-3 and complement factor H 479 [published online November 15, 2013]. Blood Transfus. doi: 10.2450/2013.0107-13.
2. Fakhouri F, Hourmant M, Cataland SR, et al. Eculizumab (ECU) inhibits throm-botic microangiopathy (TMA) and improves renal function in adult patients (pts) with atypical hemolytic uremic syndrome (aHUS) [ASH abstract 2179]. Blood. 2013;122(21)(suppl).
3. Fakhouri F, Jablonski M, Lepercq J, et al. Factor H, membrane cofactor protein, and factor I mutations in patients with hemolysis, elevated liver enzymes, and low platelet count syndrome. Blood. 2008;112(12):4542-4545.
4. Fakhouri F, Roumenina L, Provot F, et al. Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J Am Soc Nephrol. 2010;21(5):859-867.
5. Flood VH, Gill JC, Friedman KD, et al; Zimmerman Program Investigators. Collagen binding provides a sensitive screen for variant von Willebrand disease. Clin Chem. 2013;59(4):684-691.
6. Jodele S, Licht C, Goebel J, et al. Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated throm-botic microangiopathy. Blood. 2013;122(12):2003-2007.
7. Laurence J. Atypical hemolytic uremic syndrome (aHUS): making the diagnosis. Clin Adv Hematol Oncol. 2012;10(10)(suppl 17):1-12.
8. Nichols WL, Hultin MB, James AH, et al. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia. 2008;14(2):171-232.
9. Smith RJ, Alexander J, Barlow PN, et al; Dense Deposit Disease Focus Group. New approaches to the treatment of dense deposit disease. J Am Soc Nephrol. 2007;18(9):2447-2456.